NCT02561455View on ClinicalTrials.gov

Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

May 3, 2016

Primary Completion Date

July 28, 2020

Study Completion Date

July 28, 2020

Conditions
Advanced Solid TumorsAcute Myeloid Leukemia
Interventions
DRUG

Gilteritinib

oral tablet

Trial Locations (7)

10032

Site US10006, New York

10065

Site US10007, New York

17033

Site US10004, Hershey

19104

Site US10008, Philadelphia

21201

Site US10003, Baltimore

44195

Site US10001, Cleveland

85084

Site US10005, Phoenix

All Listed Sponsors
lead

Astellas Pharma Global Development, Inc.

INDUSTRY

NCT02561455 - Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial | Biotech Hunter | Biotech Hunter